Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ...

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

Conference call with CEO Dr. Marianne De Backer to be held on November 5 at 10:30 am. Webcast Link Published first on TheFly – the ...

GET MORE AI-GENERATED SIGNALS: November 05, 2024, 01:08 am ET, BY Tyler- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short VIR slightly under 9.87, target 8.38, stop loss @ 9.9 Check ...

Vir Biotechnology (VIR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick ...

Q3 2024 Earnings Call Transcript October 31, 2024 Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is ...

Third Quarter 2024 Results Key Financial Results Revenue: US$2.38m (down 9.8% from ...

Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer. The stock rose 25% to $9.34 in midday trading on Friday. Shares ...

On Friday, Vir Biotechnology Inc (VIR) stock saw a modest uptick, ending the day at $9.26 which represents a slight increase of $1.77 or 23.63% from the prior close of $7.49. The stock opened at $7.14 ...

Check the time stamp on this data. Updated AI-Generated Signals for Vir Biotechnology Inc. (VIR) available here: VIR.

“This quarter was transformational for Vir. We have bolstered our clinical pipeline with three potential best-in-class dual-masked T-cell engagers in oncology, and have sharpened our focus ...

SAN ANTONIO - An Indian comedian is bringing his international comedy tour to the Alamo City!On Nov. 16, International Emmy Award-winning comedian and actor Vir ...